[The pharmacokinetic and pharmacodynamic characteristics of foridon during interaction with the metabolic oxidation inhibitor dopegit].
The paper deals with some aspects of the effects produced by dopegite on the pharmacokinetics and pharmacodynamics of foridone from a group of calcium antagonists. Nineteen patients with essential hypertension received a single doses of foridone of 40 mg, then its course therapy in a dose of 90 mg/day for 2 weeks, then it was supplemented with dopegite in a dose of 750 mg/day for 2 weeks too. Supplementation of dopegite caused statistically significant changes as higher plasma concentrations of foridone and increased concentration-time curve areas, decreased total peripheral resistance and regional, and a lower spasm index. Dopegite can be used to enhance the antihypertensive effect of foridone.
Kukes
V G
VG
Alekhin
S N
SN
Rumiantsev
A S
AS
Gneushev
E T
ET
Gushchin
A S
AS
Germanov
D V
DV
D000328:Adult; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008750:Methyldopa / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D009543:Nifedipine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D010084:Oxidation-Reduction / Q000187:drug effects; D013997:Time Factors
D002121:Calcium Channel Blockers; D008750:Methyldopa; D009543:Nifedipine; C045912:ryodipine
Osobennosti farmakokinetiki i farmakodinamiki foridona pri vzaimodeĭstvii s ingibitorom metabolicheskogo okisleniia dopegitom.